Breaking News Instant updates and real-time market news.

AZRX

AzurRx BioPharma

$2.61 /

+0.015 (+0.58%)

14:32
05/20/19
05/20
14:32
05/20/19
14:32

AzurRx BioPharma reports 'positive' secondary endpoint data in MS1819-SD study

AzurRx BioPharma released new data for its lead development candidate MS1819-SD at the 2019 Digestive Disease Week Conference. The presentation entitled "Results from a Phase II Study of MS1819, a Recombinant Lipase for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Chronic Pancreatitis" was delivered by Dr. Nam Q. Nguyen, et al., on May 20, 2019. In addition to previously released coefficient of fat absorption results and safety assessments, Dr. Nguyen discussed newly released positive secondary endpoint data from the study. At the highest dose of 2,240 mg/day used in the study, statistical significance was achieved with the following endpoints: improvement in stool consistency, reduction in the number of bowel movements, reduction in the incidence of steatorrhea, and a trend in the reduction of abdominal discomfort on the visual analogue scale, recorded from a mean of 21.0 during baseline to 14.5 at the highest dose of 2,240 mg, at a p value of 0.148. Finally, with regard to CFA, it was observed that improvements were most pronounced in patients with baseline CFA of less than 40. Professor Nguyen, an investigator in the study and the Head of Education and Research, Interventional & EUS endoscopist, at the Royal Adelaide Hospital in Australia commented that "the efficacy results of the MS1819-SD study point to the potential of a novel and non-porcine based recombinant therapy to safely and effectively improve the nutritional status and ease of digestion of CP patients with EPI and markedly reduce associated symptoms."

AZRX AzurRx BioPharma
$2.61 /

+0.015 (+0.58%)

02/14/19 Maxim
AzurRx BioPharma initiated with a Buy at Maxim
01/25/19
Fly Intel: Top five analyst initiations
01/25/19 Roth Capital
AzurRx BioPharma initiated with a Buy at Roth Capital
10/17/18
On The Fly: Top five analyst initiations

TODAY'S FREE FLY STORIES

Earnings
Sina reports Q4 adj. EPS $1.17, consensus 74c » 05:35
02/26/20
02/26
05:35
02/26/20
05:35
SINA

Sina

$35.35 /

-0.58 (-1.61%)

Reports Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
National Energy Services reports Q4 adj. EPS 21c, consensus 21c » 05:32
02/26/20
02/26
05:32
02/26/20
05:32
NESR

National Energy Services

$7.89 /

-0.02 (-0.25%)

Reports Q4 revenue $185M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Marathon Petroleum refinery in Los Angeles in flames after explosion » 05:30
02/26/20
02/26
05:30
02/26/20
05:30
MPC

Marathon Petroleum

$53.09 /

-2.78 (-4.98%)

A Marathon Petroleum…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Home Depot price target raised to $270 from $245 at Stifel » 05:26
02/26/20
02/26
05:26
02/26/20
05:26
HD

Home Depot

$237.41 /

-2.36 (-0.98%)

Stifel analyst John Baugh…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Volaris reports Q4 EPS 68c, may not compare to consensus (2c) » 05:25
02/26/20
02/26
05:25
02/26/20
05:25
VLRS

Volaris

$12.33 /

-0.19 (-1.52%)

Reports Q4 revenue $516M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
GW Pharmaceuticals Q1 guidance 'overly conservative,' says Piper Sandler » 05:24
02/26/20
02/26
05:24
02/26/20
05:24
GWPH

GW Pharmaceuticals

$116.77 /

-4.1 (-3.39%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Campbell Soup reinstated with a Neutral at Goldman Sachs » 05:18
02/26/20
02/26
05:18
02/26/20
05:18
CPB

Campbell Soup

$47.87 /

-0.15 (-0.31%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Insulet should be bought on selloff from guidance, says Piper Sandler » 05:14
02/26/20
02/26
05:14
02/26/20
05:14
PODD

Insulet

$197.03 /

-10.46 (-5.04%)

Insulet last night…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Salesforce results strong across the board, says Jefferies » 05:11
02/26/20
02/26
05:11
02/26/20
05:11
CRM

Salesforce

$181.65 /

-4.26 (-2.29%)

Salesforce last night…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Evolent Health price target raised to $17 from $10.15 at Piper Sandler » 05:07
02/26/20
02/26
05:07
02/26/20
05:07
EVH

Evolent Health

$10.18 /

-1.13 (-9.99%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Regeneron downgraded to Neutral from Outperform at Baird » 05:04
02/26/20
02/26
05:04
02/26/20
05:04
REGN

Regeneron

$442.34 /

+16.05 (+3.77%)

, NVS

Novartis

$88.01 /

-2.06 (-2.29%)

Baird analyst Brian…

Baird analyst Brian Skorney downgraded Regeneron Pharmaceuticals (REGN) to Neutral from Outperform with an unchanged price target of $410. The stock closed Tuesday up 4% to $442.35. The analyst appreciates the "tailwind granted by safety concerns" related to Eylea competitor, Novartis' (NVS) Beovu, he notes the shares are up 50% since his August 2019 upgrade. While the fall of Beovu certainly near-term pressure on Eylea market share, this has now been accounted for in the share price, Skorney tells investors in a research note. Skorney adds that while Dupixent and Regeneron's pipeline "continue to look good," he prefers to take a "wait and see approach."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Intercept upgraded to Buy from Neutral at Citi » 04:58
02/26/20
02/26
04:58
02/26/20
04:58
ICPT

Intercept

$84.52 /

-6.25 (-6.89%)

Citi analyst Joel Beatty…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
E-Trade downgraded to Market Perform from Outperform at Raymond James » 04:56
02/26/20
02/26
04:56
02/26/20
04:56
ETFC

E-Trade

$48.52 /

-1.88 (-3.73%)

, MS

Morgan Stanley

$48.02 /

-1.65 (-3.32%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Toll Brothers downgraded to Market Perform from Outperform at Raymond James » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
TOL

Toll Brothers

$44.28 /

-2.765 (-5.88%)

Raymond James analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
nLight management to meet with Craig-Hallum » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
LASR

nLight

$16.30 /

-0.61 (-3.61%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Cerence management to meet with Oppenheimer » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
CRNC

Cerence

$26.49 /

-0.16 (-0.60%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Flowserve management to meet with RBC Capital » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
FLS

Flowserve

$41.75 /

-1.82 (-4.18%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Week of 2/21 MBA Mortgage Applications to be released at 07:00  04:55
02/26/20
02/26
04:55
02/26/20
04:55
 
Conference/Events
Ares Capital management to meet with JPMorgan » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
ARCC

Ares Capital

$17.86 /

-0.815 (-4.36%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
HyreCar management to meet with Susquehanna » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
HYRE

HyreCar

$3.63 /

-0.16 (-4.22%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
MKS Instruments management to meet with KeyBanc » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
MKSI

MKS Instruments

$101.93 /

-3.16 (-3.01%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 8 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Vocera management to meet with RBC Capital » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
VCRA

Vocera

$26.64 /

+0.59 (+2.26%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
IFF management to meet with UBS » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
IFF

IFF

$124.00 /

-3.92 (-3.06%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 7 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Amedisys management to meet with SunTrust » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
AMED

Amedisys

$184.73 /

-7.87 (-4.09%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Jack Henry management to meet with Stephens » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
JKHY

Jack Henry

$163.71 /

-4.39 (-2.61%)

Meetings to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.